Objectives: As part of the multicentre Antibiotic Therapy Optimisation Study, MIC values of 19 non-b-lactam agents were determined for third-generation cephalosporin-resistant Escherichia coli, Klebsiella species and Enterobacter species (3GCREB) isolates collected in German hospitals.
Introduction
Resistance to b-lactam antibiotics among Gram-positive and -negative organisms remains one of the most significant threats to the efficacy of this class of antimicrobial agents. 1 In particular
Gram-negative MDR organisms (MDROs) are of particular concern. Such pathogens include Klebsiella pneumoniae, Escherichia coli and Enterobacter spp. 2 Enterobacteriaceae resistant to thirdgeneration cephalosporins (3GCREB) have spread dramatically V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
over the last decades. Among 3GCREB, resistance is mostly due to b-lactam-hydrolysing enzymes, particularly ESBLs, which are a heterogeneous group of enzymes. Apart from ESBLs, resistance to third-generation cephalosporins can also be caused by the production of the AmpC b-lactamase found particularly in Enterobacter, Citrobacter, Morganella and Serratia spp., but can also be detected in E. coli and K. pneumoniae.
The aim of the present study was to evaluate the MIC distributions of 19 antimicrobial agents other than b-lactams for a collection of German 3GCREB isolates from different tertiary care hospitals across the country. The study is part of the Antibiotic Therapy Optimisation Study (ATHOS), which is the largest prevalence study on 3GCREB carriage upon hospital admission in Europe and delivers important insight into susceptibility distributions among German MDROs. 3 
Methods

Study design
In the present study isolates were collected in 2014 at six large tertiary care hospitals, covering the North, West, East, Southwest and Southeast of Germany as part of the multicentre ATHOS. Centres had between 1300 and 3200 inpatient beds. Patients 18 years from general wards that had been admitted between June and December 2014 and gave their informed consent, were included in the study. Patients from ICUs, dermatology, obstetrics, ophthalmology, otorhinolaryngology and psychiatry were excluded.
Ethics
The study was approved by the institutional ethics committees.
Selection of bacterial strains
Study patients were screened for 3GCREB colonization within 72 h of admission using rectal swabs or stool samples. Screening of patients for 3GCREB was done by plating rectal swabs or stool samples on ChromID ESBL agar (bioMérieux, Marcy-l' Etoile, France). Species identification of isolates growing on ESBL agar was performed using MALDI-TOF MS or the Vitek2 GN ID card (bioMérieux). Susceptibility testing was carried out using Vitek2 (bioMérieux). All isolates that were non-susceptible to cefotaxime, ceftriaxone or ceftazidime according to EUCAST breakpoints were included in the study and further characterized. Phenotypic detection of ESBL production was performed with the combination disc test as recommended by EUCAST, using cefotaxime, ceftazidime and cefepime + clavulanate and tested for AmpC production by cefoxitin/cloxacillin disc test. Carbapenemase-producing isolates from the ATHOS prevalence study were not included in our study.
Antimicrobial susceptibility testing
Study isolates underwent susceptibility testing with carbapenems (meropenem and ertapenem), fluoroquinolones (levofloxacin and moxifloxacin), aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin and paromomycin), tetracyclines (tetracycline, minocycline and tigecycline), macrolides (erythromycin, clarithromycin and azithromycin) and miscellaneous agents [trimethoprim/sulfamethoxazole, chloramphenicol, nitrofurantoin, colistin and fosfomycin intravenous (iv)]. Isolates were tested by broth microdilution antimicrobial susceptibility testing with the MICRONAUT system (Merlin Diagnostika, Bornheim-Hersel, Germany) according to standard procedures ISO 20776-1:2006. 
Results and discussion
To the best of our knowledge, ATHOS represents the largest study on the prevalence of 3GCREB carriage on hospital admission in Europe, including .4000 patients admitted to six tertiary care hospitals representing different regions of Germany. 3 Of the collected isolates, 328 E. coli, 35 Klebsiella spp.
(1 Klebsiella oxytoca and 34 K. pneumoniae) and 16 Enterobacter spp. (1 Enterobacter aerogenes and 15 Enterobacter cloacae) isolates non-susceptible to third-generation cephalosporins were available for susceptibility testing in our study. All tested isolates were fully susceptible to meropenem and ertapenem ( Table 1) . Results of MIC tests are shown in Tables 1-3 . Susceptibility data were reviewed against 2016 EUCAST breakpoints. The emergence of resistance among 3GCREB is a matter of concern due to the widespread use of antibiotics including carbapenems. 5 Systematic investigations on resistance trends are performed in many different countries or institutions, but many investigations concentrate on oral antibiotics or focus on important classes of antibiotics such as fluoroquinolones or carbapenems, but cannot pay attention to uncommon and seldom used agents such as chloramphenicol or macrolides in the context of infections due to 3GCREB infections. 6 Other studies report fluoroquinolone resistance rates among 3GCREB of one-third to two-thirds of the isolates tested, which was similar in our study with higher resistance rates (i.e. levofloxacin MIC .2 mg/L) for E. coli (128/328) than Klebsiella spp. (8 of 35), but lower for Enterobacter spp. (1 of 16) ( Table 2) . 7 Resistance to moxifloxacin (EUCAST breakpoint 1 mg/L) was even higher among the isolates, ranging from 2 of 16 for Enterobacter spp. to 134 of 328 for E. coli. High rates of resistance to trimethoprim/sulfamethoxazole (EUCAST breakpoint 4/76 mg/L) for E. coli and Klebsiella spp. (.70%) were expected, but, interestingly, the rate of resistance to trimethoprim/ sulfamethoxazole was lower for Enterobacter spp. (5 of 16) ( Table 1) . 8 Treatment options of reserve comprise colistin and fosfomycin iv for which resistance rates fortunately are still very low (Table 1) . Despite the worldwide appearance of mcr-1-mediated colistin resistance our resistance rates still tend be to almost zero. 9 In our study, fosfomycin iv resistance among Enterobacter spp. was higher (6 of 16) than for E. coli (5 of 328) and Klebsiella spp. (5 of 35) . This fact was also reported in other studies. 10 EUCAST breakpoints for nitrofurantoin refer to uncomplicated urinary tract infection only and strictly only to E. coli. Applying the breakpoint of 64 mg/L to all species significantly more Klebsiella spp. (12 of 35) isolates are resistant (Table 1) . Nitrofurantoin use is increasing because of increasing resistance to other antimicrobials, but use for systemic infections is not recommended. 11 Chloramphenicol was used frequently in the past, but was nearly abandoned due to relevant side effects. Data on resistance rates are available for carbapenem-resistant Gram-negatives, but not for current 3GCREB collections. 12 In our collection, 20% of the isolates tested are resistant (EUCAST breakpoint 8 mg/L). Comparative data among aminoglycosides, macrolides and tetracyclines for German 3GCREB do not exist to our knowledge. A previous study also showed that amikacin and tobramycin (resistance breakpoints 16 and 4 mg/L) have good activity against 3GCREB, whereas susceptibility rates for gentamicin (resistance breakpoint 4 mg/L) are more elevated (Table 2) . 13 Breakpoints for streptomycin are not available, but also generally more elevated, i.e. 119 of 328 E. coli, 14 of 35 Klebsiella spp. and 3 of 16 Enterobacter spp. have an MIC .32 mg/L. Neomycin and paromomycin have low rates beyond 4 mg/L (Table 2 ), but systemic use is only possible in exceptional situations due to the excess of toxicity. The latter agents have been investigated in the context of intestinal decolonization of 3GCREB in the gut. 14, 15 We doubt that the two agents are used in the iv formulations in a relevant number worldwide. Among macrolides for which no EUCAST breakpoints are available for Gram-negatives, only azithromycin is referred to for the treatment of Salmonella Typhi or Shigella spp. infections with less elevated percentages of isolates with an MIC .32 mg/L. For the tetracyclines, only tigecycline has defined EUCAST breakpoints despite the fact that tigecycline resistance testing has always led to a 
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Resistant isolates according to EUCAST breakpoints are shaded grey. For streptomycin, neomycin and paromomycin no breakpoints are available.
Antimicrobial activity against Enterobacteriaceae in Germany JAC controversial discussion about the right method and media. 16 Tigecycline resistance-defined as an MIC .2 mg/L with media prepared fresh on the day of use-was only found in 1 of 16 Enterobacter spp., but none of the E. coli or Klebsiella spp. isolates (Table 3 ). Minocycline was recently tested against extremely drugresistant Acinetobacter baumannii, but its usefulness against Enterobacteriaceae remains to be investigated. 17 Our study has a few minor limitations. As for all studies on antimicrobial resistance trends we cannot guarantee that the collection of isolates is representative for Germany. Nevertheless, ATHOS was the largest study on 3GCREB carriage upon Europe and comprises many important tertiary care hospitals from different regions in Germany. With .4000 patients screened on admission we are quite sure that our data can give good insight into the MIC distributions of agents and can therefore be considered representative to a certain extent for the whole of Germany. Some agents tested that resulted in low MICs have to be evaluated in a clinical context, i.e. randomized clinical trial to assess its usefulness fully.
Conclusions
Overall, our study gives insight into non-b-lactam MIC distributions for a collection of German 3GCREB isolates. The study therefore delivers data on previously unreported antimicrobial activity and might influence clinical practice in infections due to 3GCREB. Continuous monitoring of evolutionary trends in the susceptibility profiles of 3GCREB in Germany is crucial. Further prospective and comparative clinical studies are warranted to assess fully the clinical potential of the tested agents in serious infections due to MDROs. Mischnik et al.
